Efficacy and predictors of rechallenge with immune checkpoint inhibitors in non‐small cell lung cancer
Author:
Affiliation:
1. Department of Respiratory Medicine Kanazawa Medical University Kahoku‐gun Ishikawa Japan
Publisher
Wiley
Subject
Pulmonary and Respiratory Medicine,Oncology,General Medicine
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1111/1759-7714.14309
Reference28 articles.
1. Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
2. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
3. Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
4. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
5. Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Cited by 8 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Efficacy of rechallenge immunotherapy after immune monotherapy resistance in patients with advanced non-small cell lung cancer;Journal of Cancer Research and Clinical Oncology;2023-11-17
2. Immunologic constant of rejection as a predictive biomarker of immune checkpoint inhibitors efficacy in non-small cell lung cancer;Journal of Translational Medicine;2023-09-19
3. Disease progression status during initial immune checkpoint inhibitor (ICI) affects the clinical outcome of ICI retreatment in advanced non‐small cell lung cancer patients;Cancer Medicine;2023-04-16
4. Immunotherapies;Reactions Weekly;2023-04-15
5. The Flip of the Coin of Personalized Cancer Immunotherapy: A Focused Review on Rare Immune Checkpoint Related Adverse Effects;Immune Checkpoint Inhibitors - New Insights and Recent Progress;2023-03-08
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3